Evidence map›Paper›PMID 21584767›Full record

ReviewWiener medizinische Wochenschrift (1946)2011

Insulin therapy.

Monika Lechleitner, Friedrich Hoppichler

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. A Dioxidovanadium ComplexEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  2. Relationship Between Portal HTN and Cirrhosis as a Cause for Diabetes.Journal of translational internal medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Monika LechleitnerLandeskrankenhaus Hochzirl, Anna Dengel-Haus, Zirl, Austria. monika.lechleitner@tilak.at
Friedrich Hoppichler
Hospital of the Brothers of St. John of God · ATLandeskrankenhaus Feldkirch · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus. In type 2 diabetes, insulin is indicated if glycaemic goals are not reached by oral anti diabetics, as well as for metabolic detoriation, co-morbidities, surgery, pregnancy or contradictions against oral anti diabetics. Insulin preparations are characterized by the onset of the insulin action, the peak profile and duration of action. Available are short acting, long-acting and premixed preparations of human insulin, and insulin analogues. The gold standard of insulin therapy in type 1 diabetes is functional insulin therapy with a basal-bolus insulin regimen and control and adaption of the therapy by the patient. Various insulin regimens are available for treating patients with type 2 diabetes, including basal insulin supported oral therapy, supplementary mealtime injection of short acting insulin or insulin analogues, conventional insulin therapy or a basal bolus procedure. The various insulin preparations and regimens make it possible to adapt the therapy according to the patient's individual need.

Indexed as

Delayed-Action PreparationsDiabetes ComplicationsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Drug Administration ScheduleHumansHypoglycemic AgentsInjections, SubcutaneousInsulinDelayed-Action PreparationsHypoglycemic AgentsInsulin

Identifiers

PMID21584767
OpenAlexW4246307891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.